J
Jean-Michel Pawlotsky
Researcher at University of Paris
Publications - 539
Citations - 37991
Jean-Michel Pawlotsky is an academic researcher from University of Paris. The author has contributed to research in topics: Hepatitis C virus & Hepatitis C. The author has an hindex of 94, co-authored 503 publications receiving 34340 citations. Previous affiliations of Jean-Michel Pawlotsky include French Institute of Health and Medical Research & IMRB International.
Papers
More filters
Journal ArticleDOI
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky,Alessio Aghemo,Geoffrey Dusheiko,Xavier Forns,Massimo Puoti,Christophe Sarrazin +5 more
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Journal ArticleDOI
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
C.P.G.P.P. Marcellin,G.M. Dusheiko,Fabien Zoulim,Rafael Esteban,Stephanos J. Hadziyannis,Pietro Lampertico,M.P. Manns,Daniel Shouval,Cihan Yurdaydin,R.A. Craxi,Xavier Forns,Darius Moradpour,Jean-Michel Pawlotsky,Jörg Petersen,H.W.F. Easl +14 more
TL;DR: The objective of these EASL Clinical Practice Guidelines is to update recommendations for the optimal management of chronic hepatitis B (CHB) and the CPGs do not focus on prevention and vaccination.
Journal ArticleDOI
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
Peter Simmonds,Jens Bukh,Christophe Combet,Gilbert Deléage,Nobuyuki Enomoto,Stephen M. Feinstone,Phillippe Halfon,Geneviève Inchauspé,Carla Kuiken,Geert Maertens,Masashi Mizokami,Donald G. Murphy,Hiroaki Okamoto,Jean-Michel Pawlotsky,François Penin,Erwin Sablon,Tadasu Shin-I,Lieven Stuyver,Heinz-Jürgen Thiel,Sergei Viazov,Amy J. Weiner,Anders Widell +21 more
TL;DR: These proposals provide the framework by which the HCV databases store and provide access to data on HCV, which will internationally coordinate the assignment of new genotypes and subtypes in the future.
Journal ArticleDOI
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode,Nicole Forestier,Geoffrey Dusheiko,Peter Ferenci,Stanislas Pol,Tobias Goeser,Jean-Pierre Bronowicki,Marc Bourlière,Shahin Gharakhanian,Leif Bengtsson,Lindsay McNair,Shelley George,Tara L. Kieffer,Ann D. Kwong,Robert S. Kauffman,John Alam,Jean-Michel Pawlotsky,Stefan Zeuzem +17 more
TL;DR: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy.
Journal ArticleDOI
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Giovanni Raimondo,Jean-Pierre Allain,Maurizia Rossana Brunetto,Marie Annick Buendia,Ding-Shinn Chen,Massimo Colombo,Antonio Craxì,Francesco Donato,Carlo Ferrari,Giovanni Battista Gaeta,Wolfram H. Gerlich,Massimo Levrero,Stephen Locarnini,Thomas I. Michalak,Mario U. Mondelli,Jean-Michel Pawlotsky,Teresa Pollicino,Daniele Prati,Massimo Puoti,Didier Samuel,Daniel Shouval,Antonina Smedile,Giovanni Squadrito,Christian Trepo,Erica Villa,Hans Will,Alessandro Zanetti,Fabien Zoulim +27 more
TL;DR: Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H. Gerlich,Massimo Levrero, Stephen Locarnini, Thomas Michalak, Mario U. Zanetti, Fabien Zoulim